申请人:Jeong Shin Lak
公开号:US20050256143A1
公开(公告)日:2005-11-17
Disclosed are purine nucleoside compounds that are selective to A
3
adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: wherein X is sulfur or oxygen; R
1
is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R
2
is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R
3
and R
3′
are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocabonyl, whereas R
3
and R
3
′ do not have identical substituents simultaneously; and R
4
is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a method for preventing or treating various diseases, state, or condition, including asthma, inflammation, cerebral ischemia, heart diseases, and cancer.
揭示了对A3腺苷受体具有选择性的嘌呤核苷化合物,可用于治疗癌症和炎症性疾病。所述化合物由以下一般式(I)表示,包括其异构体:其中X为硫或氧;R1为氢、烷基、苄基、卤代苄基或苯基烷基;R2为氢、卤素、烷氧基、烯基、炔基、烷基硫基或硫基;R3和R3'为氢、羟基烷基、烷氧羰基或烷基氨羰基,其中R3和R3'不同时具有相同的取代基;R4为氢或烷基。还揭示了一种包含一种式(I)的化合物、其异构体或其药理学上可接受的盐作为活性成分的药物组合物,以及一种用于预防或治疗各种疾病、状态或症状的方法,包括哮喘、炎症、脑缺血、心脏疾病和癌症。